Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Short summary

Pembrolizumab demonstrated antitumor activity in advanced non-small-cell lung cancer (NSCLC), with an objective response rate of 19.4% and a median overall survival of 12.0 months across all patients (n=495). A PD-L1 expression level of at least 50% in tumor cells identified a subgroup with significantly improved efficacy, showing a 45.2% response rate and a median progression-free survival of 6.3 months.

AI-generated from the title and abstract; the full text is not read.